Phase II prefusion non-stabilised Covid-19 mRNA vaccine randomised study

Simple item page
dc.contributor.authorPuthanakit T.
dc.contributor.authorPrompetchara E.
dc.contributor.authorGatechompol S.
dc.contributor.authorKetloy C.
dc.contributor.authorThitithanyanont A.
dc.contributor.authorJongkaewwattana A.
dc.contributor.authorBuranapraditkun S.
dc.contributor.authorUbolyam S.
dc.contributor.authorKerr S.J.
dc.contributor.authorSophonphan J.
dc.contributor.authorApornpong T.
dc.contributor.authorKittanamongkolchai W.
dc.contributor.authorSiwamogsatham S.
dc.contributor.authorSriplienchan S.
dc.contributor.authorPatarakul K.
dc.contributor.authorTheerawit T.
dc.contributor.authorPromsena P.
dc.contributor.authorNantanee R.
dc.contributor.authorManomaisantiphap S.
dc.contributor.authorChokyakorn S.
dc.contributor.authorHong L.
dc.contributor.authorSamija M.
dc.contributor.authorMontefiori D.C.
dc.contributor.authorGao H.
dc.contributor.authorEaton A.
dc.contributor.authorWijagkanalan W.
dc.contributor.authorAlameh M.G.
dc.contributor.authorWeissman D.
dc.contributor.authorRuxrungtham K.
dc.contributor.authorTawan M.
dc.contributor.authorSutjarit A.
dc.contributor.authorMeepuksom T.
dc.contributor.authorAthipunjapong J.
dc.contributor.authorJupimai T.
dc.contributor.authorMoonwong J.
dc.contributor.authorNadsasarn R.
dc.contributor.authorKhamthi S.
dc.contributor.authorNuncharoen P.
dc.contributor.authorChanpoom Y.
dc.contributor.authorKhamkhen P.
dc.contributor.authorNarupan N.
dc.contributor.authorThongthip S.
dc.contributor.authorSoisoongnern K.
dc.contributor.authorShanyip C.
dc.contributor.authorRachpradit T.
dc.contributor.authorSriphraram K.
dc.contributor.authorSomhanwong W.
dc.contributor.authorBoondamnern T.
dc.contributor.authorBoonnak N.
dc.contributor.authorChomchey N.
dc.contributor.authorTipsuk S.
dc.contributor.authorPuttamaswin S.
dc.contributor.authorYewande S.
dc.contributor.authorLertarom P.
dc.contributor.authorUanithirat A.
dc.contributor.authorAnuchadbut A.
dc.contributor.authorChanthaburanun S.
dc.contributor.authorTarawat K.
dc.contributor.authorMahanontharit A.
dc.contributor.authorSinthon W.
dc.contributor.authorPlakunmonthonw S.
dc.contributor.authorWongmueang S.
dc.contributor.authorDalodom T.
dc.contributor.authorSopa B.
dc.contributor.authorPhongam N.
dc.contributor.authorSri-Arunsak A.
dc.contributor.authorChobkarching U.
dc.contributor.authorBouko C.
dc.contributor.authorJunseeha S.
dc.contributor.authorPhuphalicho B.
dc.contributor.authorPingthaisong P.
dc.contributor.authorKhlaiphuengsin A.
dc.contributor.authorPararit P.
dc.contributor.authorEamyoung P.
dc.contributor.authorSomjit T.
dc.contributor.authorIampornsin T.
dc.contributor.authorThongchomphunut D.
dc.contributor.authorManopwisedjaroen S.
dc.contributor.authorLaopanupong T.
dc.contributor.authorEkronarongchai S.
dc.contributor.authorSrisaowakarn C.
dc.contributor.authorJantraphakorn Y.
dc.contributor.authorSrisutthisamphan K.
dc.contributor.authorGrandin P.V.
dc.contributor.correspondencePuthanakit T.
dc.contributor.otherMahidol University
dc.date.accessioned2024-02-08T18:17:41Z
dc.date.available2024-02-08T18:17:41Z
dc.date.issued2024-12-01
dc.description.abstractChulaCov19 mRNA vaccine demonstrated promising phase 1 results. Healthy adults aged 18–59 years were double-blind randomised 4:1 to receive two intramuscular doses of ChulaCov19 50 µg or placebo. Primary endpoints were safety and microneutralization antibody against-wild-type (Micro-VNT50) at day 50. One hundred fifty adults with median (IQR) age 37 (30–46) years were randomised. ChulaCov19 was well tolerated, and most adverse events were mild to moderate and temporary. Geometric mean titres (GMT) of neutralizing titre against wild-type for ChulaCov19 on day 50 were 1367 IU/mL. T-cell IFN-γ-ELISpot showed the highest responses at one week (Day29) after dose 2 then gradually declined. ChulaCov19 50 µg is well tolerated and elicited high neutralizing antibodies and strong T-cell responses in healthy adults. Trial registration number: ClinicalTrials.gov Identifier NCT04566276, 28/09/2020.
dc.identifier.citationScientific Reports Vol.14 No.1 (2024)
dc.identifier.doi10.1038/s41598-023-49653-6
dc.identifier.eissn20452322
dc.identifier.scopus2-s2.0-85183624400
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/95914
dc.rights.holderSCOPUS
dc.subjectMultidisciplinary
dc.titlePhase II prefusion non-stabilised Covid-19 mRNA vaccine randomised study
dc.typeArticle
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85183624400&origin=inward
oaire.citation.issue1
oaire.citation.titleScientific Reports
oaire.citation.volume14
oairecerif.author.affiliationDuke University Medical Center
oairecerif.author.affiliationThe Kirby Institute
oairecerif.author.affiliationThe HIV Netherlands Australia Thailand Research Collaboration
oairecerif.author.affiliationArmed Forces Research Institute of Medical Sciences, Thailand
oairecerif.author.affiliationMahidol University
oairecerif.author.affiliationThailand National Center for Genetic Engineering and Biotechnology
oairecerif.author.affiliationUniversity of Pennsylvania Perelman School of Medicine
oairecerif.author.affiliationFaculty of Medicine, Chulalongkorn University
oairecerif.author.affiliationGenevant Sciences Corporation
oairecerif.author.affiliationCo. Ltd.
oairecerif.author.affiliationSEARCH

Files

Collections

Scopus 2024